Literature DB >> 21030477

Proton MR spectroscopy provides relevant prognostic information in high-grade astrocytomas.

C Majós1, J Bruna, M Julià-Sapé, M Cos, A Camins, M Gil, J J Acebes, C Aguilera, C Arús.   

Abstract

BACKGROUND AND
PURPOSE: There is a large range of survival times in patients with HGA that can only be partially explained by histologic grade and clinical aspects. This study aims to retrospectively assess the predictive value of single-voxel (1)H-MRS regarding survival in HGA.
MATERIALS AND METHODS: Pretreatment (1)H-MRS in 187 patients with HGA produced 180 spectra at STE (30 ms) and 182 at LTE (136 ms). Patients were dichotomized into 2 groups according to survival better or worse than the median. The spectra of the 2 groups were compared using the Mann-Whitney U test. The points on the spectrum with the most significant differences were selected for discriminating patients with good and poor prognosis. Thresholds were defined with ROC curves, and survival was analyzed by using the Kaplan-Meier method and the Cox proportional hazards model.
RESULTS: Four points on the spectrum showed the most significant differences: 0.98 and 3.67 ppm at STE; and 0.98 and 1.25 ppm at LTE (P between <.001 and .011). These points were useful for stratifying 2 prognostic groups (P between <.001 and .003, Kaplan-Meier). The Cox forward stepwise model selected 3 spectroscopic variables: the intensity values of the points 3.67 ppm at STE (hazard ratio, 2.132; 95% CI, 1.504-3.023), 0.98 ppm at LTE (hazard ratio, 0.499; 95% CI, 0.339-0.736), and 1.25 ppm at LTE (hazard ratio, 0.574; 95% CI, 0.368-0.897).
CONCLUSIONS: (1)H-MRS is of value in predicting the length of survival in patients with HGA and could be used to stratify prognostic groups.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21030477      PMCID: PMC7964967          DOI: 10.3174/ajnr.A2251

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  26 in total

1.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Authors:  Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

2.  Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging.

Authors:  Ryuji Murakami; Takeshi Sugahara; Hideo Nakamura; Toshinori Hirai; Mika Kitajima; Yoshiko Hayashida; Yuji Baba; Natsuo Oya; Jun-Ichi Kuratsu; Yasuyuki Yamashita
Journal:  Radiology       Date:  2007-03-13       Impact factor: 11.105

3.  Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06.

Authors:  C B Scott; C Scarantino; R Urtasun; B Movsas; C U Jones; J R Simpson; A J Fischbach; W J Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-01-01       Impact factor: 7.038

Review 4.  Towards a method for automated classification of 1H MRS spectra from brain tumours.

Authors:  A R Tate; J R Griffiths; I Martínez-Pérez; A Moreno; I Barba; M E Cabañas; D Watson; J Alonso; F Bartumeus; F Isamat; I Ferrer; F Vila; E Ferrer; A Capdevila; C Arús
Journal:  NMR Biomed       Date:  1998 Jun-Aug       Impact factor: 4.044

5.  Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume.

Authors:  Joonmi Oh; Roland G Henry; Andrea Pirzkall; Ying Lu; Xiaojuan Li; Isabelle Catalaa; Susan Chang; William P Dillon; Sarah J Nelson
Journal:  J Magn Reson Imaging       Date:  2004-05       Impact factor: 4.813

6.  Taurine detection by proton magnetic resonance spectroscopy in medulloblastoma: contribution to noninvasive differential diagnosis with cerebellar astrocytoma.

Authors:  Angel Moreno-Torres; Irene Martínez-Pérez; Miguel Baquero; Jaume Campistol; Antoni Capdevila; Carles Arús; Jesus Pujol
Journal:  Neurosurgery       Date:  2004-10       Impact factor: 4.654

7.  1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas.

Authors:  Valeria Righi; Jose M Roda; José Paz; Adele Mucci; Vitaliano Tugnoli; Gemma Rodriguez-Tarduchy; Laura Barrios; Luisa Schenetti; Sebastián Cerdán; María L García-Martín
Journal:  NMR Biomed       Date:  2009-07       Impact factor: 4.044

8.  Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas.

Authors:  Xiaojuan Li; Hua Jin; Ying Lu; Joonmi Oh; Susan Chang; Sarah J Nelson
Journal:  NMR Biomed       Date:  2004-02       Impact factor: 4.044

9.  Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

Authors:  Thierry Gorlia; Martin J van den Bent; Monika E Hegi; René O Mirimanoff; Michael Weller; J Gregory Cairncross; Elizabeth Eisenhauer; Karl Belanger; Alba A Brandes; Anouk Allgeier; Denis Lacombe; Roger Stupp
Journal:  Lancet Oncol       Date:  2007-12-21       Impact factor: 41.316

10.  Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.

Authors:  Johan M Kros; Thierry Gorlia; Mathilde C Kouwenhoven; Ping-Pin Zheng; V Peter Collins; Dominique Figarella-Branger; Felice Giangaspero; Caterina Giannini; Karima Mokhtari; Sverre J Mørk; Anders Paetau; Guido Reifenberger; Martin J van den Bent
Journal:  J Neuropathol Exp Neurol       Date:  2007-06       Impact factor: 3.685

View more
  9 in total

Review 1.  Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging.

Authors:  James R Fink; Mark Muzi; Melinda Peck; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

2.  (1)H-MRS is useful to reinforce the suspicion of primary central nervous system lymphoma prior to surgery.

Authors:  Paloma Mora; Carles Majós; Sara Castañer; Juan J Sánchez; Andreu Gabarrós; Amadeo Muntané; Carles Aguilera; Carles Arús
Journal:  Eur Radiol       Date:  2014-07-17       Impact factor: 5.315

3.  Metabolomics of Glioma.

Authors:  Sizhe Feng; Yutong Liu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Functional imaging in adult and paediatric brain tumours.

Authors:  Andrew C Peet; Theodoros N Arvanitis; Martin O Leach; Adam D Waldman
Journal:  Nat Rev Clin Oncol       Date:  2012-11-13       Impact factor: 66.675

5.  Non-negative matrix factorisation methods for the spectral decomposition of MRS data from human brain tumours.

Authors:  Sandra Ortega-Martorell; Paulo J G Lisboa; Alfredo Vellido; Margarida Julià-Sapé; Carles Arús
Journal:  BMC Bioinformatics       Date:  2012-03-08       Impact factor: 3.169

Review 6.  Insights into the Chemical Biology of Childhood Embryonal Solid Tumors by NMR-Based Metabolomics.

Authors:  Melissa Quintero Escobar; Mariana Maschietto; Ana C V Krepischi; Natasa Avramovic; Ljubica Tasic
Journal:  Biomolecules       Date:  2019-12-08

7.  Metabolomic Screening of Tumor Tissue and Serum in Glioma Patients Reveals Diagnostic and Prognostic Information.

Authors:  Lina Mörén; A Tommy Bergenheim; Soma Ghasimi; Thomas Brännström; Mikael Johansson; Henrik Antti
Journal:  Metabolites       Date:  2015-09-15

8.  Characterization of the serum metabolome following radiation treatment in patients with high-grade gliomas.

Authors:  Lina Mörén; Carl Wibom; Per Bergström; Mikael Johansson; Henrik Antti; A Tommy Bergenheim
Journal:  Radiat Oncol       Date:  2016-04-02       Impact factor: 3.481

Review 9.  Multimodal Molecular Imaging: Current Status and Future Directions.

Authors:  Min Wu; Jian Shu
Journal:  Contrast Media Mol Imaging       Date:  2018-06-05       Impact factor: 3.161

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.